» Articles » PMID: 27366535

Comparison of Sugammadex Versus Neostigmine Costs and Respiratory Complications in Patients with Obstructive Sleep Apnoea

Overview
Specialty Anesthesiology
Date 2016 Jul 2
PMID 27366535
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare sugammadex and neostigmine regarding the efficacy in reversing rocuronium-induced neuromuscular block, the incidence of post-operative respiratory complications and costs in patients undergoing surgery for the treatment of obstructive sleep apnoea (OSA).

Methods: After obtaining ethical approval and patient consent, 74 patients in ASA physical status I or II were randomised into two groups to receive 2-mg kg(-1) sugammadex (Group S) or 0.04-mg kg(-1) neostigmine+0.5-mg atropine (Group N). Groups were compared regarding time to TOF (train-of-four) 0.9, operating room time, post-anaesthesia care unit (PACU) stay, post-operative respiratory complications, costs related to neuromuscular block reversal, anaesthesia care and complication treatment.

Results: Patient demographics, anaesthesia, surgical data and total rocuronium doses were similar between groups. Time to TOF 0.9 was shorter for group S [Group N: 8 (5-18) min; Group S: 2 (1.5-6) min (p<0.001)]. Operating room time [Group S: 72.4±14.3 min; Group N: 96.6±22.8 min (p<0.001)] and PACU stay [Group S: 22.9±10.1 dk; Group N: 36.3±12.6 dk (p<0.001)] were also shorter in Group S. After extubation, desaturation was observed in 12 (32.4%) patients in group N and in 4 (8%) patients in group S (p=0.048). In group N, three patients were reintubated; there were eight (21.6%) unplanned intensive care unit (ICU) admissions. There was one unplanned ICU admission in group S. Negative pressure pulmonary oedema was observed in one patient in group N. The results regarding costs were as follows. The reversal cost was higher in the sugammadex group (vial cost 98.14 TL) than that in the neostigmine group (ampoule cost 0.27 TL; total 6147.88 TL vs. 3569.5 TL); however, complication treatment cost and total cost were lower in group S than those in group N (199.5 TL vs. 3944.6 TL) (staff anaesthesia doctor cost was 0.392 TL per min and the cost of nurse anaesthetist was 0.244 TL per min).

Conclusion: This study confirmed the efficacy of sugammadex over neostigmine for the reversal of rocuronium-induced neuromuscular block. Sugammadex decreases the incidence of post-operative respiratory complications and related costs in patients with OSA.

Citing Articles

Effect of sugammadex on postoperative complications in patients with severe burn who underwent surgery: a retrospective study.

Kim J, Kim M, Oh M, Lee S, Kwon Y Sci Rep. 2024; 14(1):525.

PMID: 38177213 PMC: 10767056. DOI: 10.1038/s41598-024-51171-y.


Postoperative pulmonary complications after sugammadex reversal of neuromuscular blockade: a systematic review and meta-analysis with trial sequential analysis.

Liu H, Yu H, Zuo Y, Liang P BMC Anesthesiol. 2023; 23(1):130.

PMID: 37081384 PMC: 10116764. DOI: 10.1186/s12871-023-02094-0.


Superiority of sugammadex in preventing postoperative pulmonary complications.

Liu H, Luo R, Cao S, Zheng B, Ye L, Zhang W Chin Med J (Engl). 2023; 136(13):1551-1559.

PMID: 37027443 PMC: 10325761. DOI: 10.1097/CM9.0000000000002381.


Model for predicting early and late-onset postoperative pulmonary complications in perioperative patients receiving neuromuscular blockade: a secondary analysis.

Aragon-Benedi C, Oliver-Fornies P, Pascual-Bellosta A, Ortega-Lucea S, Ramirez-Rodriguez J, Martinez-Ubieto J Sci Rep. 2023; 13(1):5234.

PMID: 37002265 PMC: 10066373. DOI: 10.1038/s41598-023-32017-5.


Effect of patient decision aids on choice between sugammadex and neostigmine in surgeries under general anesthesia: a multicenter randomized controlled trial.

Wang L, Lin Y, Chen J, Lan W, Hung K, Chen J Korean J Anesthesiol. 2023; 76(4):280-289.

PMID: 36935388 PMC: 10391073. DOI: 10.4097/kja.22624.


References
1.
Della Rocca G, Pompei L, Pagan DE Paganis C, Tesoro S, Mendola C, Boninsegni P . Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study. Acta Anaesthesiol Scand. 2013; 57(9):1138-45. DOI: 10.1111/aas.12155. View

2.
Fuchs-Buder T, Claudius C, Skovgaard L, Eriksson L, Mirakhur R, Viby-Mogensen J . Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007; 51(7):789-808. DOI: 10.1111/j.1399-6576.2007.01352.x. View

3.
Young T, Evans L, Finn L, Palta M . Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997; 20(9):705-6. DOI: 10.1093/sleep/20.9.705. View

4.
Gupta R, Parvizi J, Hanssen A, Gay P . Postoperative complications in patients with obstructive sleep apnea syndrome undergoing hip or knee replacement: a case-control study. Mayo Clin Proc. 2001; 76(9):897-905. DOI: 10.4065/76.9.897. View

5.
den Herder C, Schmeck J, Appelboom D, de Vries N . Risks of general anaesthesia in people with obstructive sleep apnoea. BMJ. 2004; 329(7472):955-9. PMC: 524108. DOI: 10.1136/bmj.329.7472.955. View